Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 6/20 | 0.38 |
| ▸ | ABL1 | P00519 | 5/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31448089 | 0.79 | MLYCD (0.49) | MLYCDGPBAR1 | |
| SCHEMBL26621204 | 0.79 | MLYCD (0.49) | MLYCDGPBAR1 | |
| SCHEMBL14993762 | 0.79 | SCN10A (0.43) | SCN10AALPLABL1ATMOPRM1 | |
| SCHEMBL1557170 | 0.78 | HDAC8 (0.53) | MLYCDSLC6A2SLC6A4 | |
| SCHEMBL7413175 | 0.78 | CYP11B1 (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL14395852 | 0.77 | HCAR2 (0.53) | MLYCDABL1GPBAR1ATMCYP11B1 | |
| SCHEMBL4654242 | 0.77 | MLYCD (0.60) | MLYCDSLC6A2SLC6A4 | |
| SCHEMBL16244840 | 0.77 | GPBAR1 (0.48) | MLYCDGPBAR1SLC6A2SLC6A4 | |
| SCHEMBL2714656 | 0.77 | GPBAR1 (0.49) | MLYCDGPBAR1SLC6A2SLC6A4 | |
| SCHEMBL30602765 | 0.75 | SIRT2 (0.50) | SCN10AALPLABL1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2025-04-17 | — | — | US | disclosed |
| US-12209086-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2025-01-28 | — | — | US | disclosed |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-11878976-B2 | FGFR3 inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878976-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | MLYCD 672/4885SCN10A 987/4885ALPL 3593/4885 |
| US-12209086-B2 | FGFR3 inhibitor compounds | FGFR3, FGFR1, FGFR2 | MLYCD 672/4885SCN10A 987/4885ALPL 3593/4885 |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | MLYCD 672/4885SCN10A 987/4885ALPL 3593/4885 |
| US-20250122196-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | MLYCD 672/4885SCN10A 987/4885ALPL 3593/4885 |
| US-20230095122-A1 | FGFR3 INHIBITOR COMPOUNDS | FGFR3, FGFR1, FGFR2 | MLYCD 672/4885SCN10A 987/4885ALPL 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.